Correction to: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an In
- PDF / 186,018 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 30 Downloads / 204 Views
Correction Correction to: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective Arian Emami Riedmaier,1,24 Kevin DeMent,2 James Huckle,3 Phil Bransford,4 Cordula Stillhart,5 Richard Lloyd,6 Ravindra Alluri,7 Sumit Basu,8 Yuan Chen,9 Varsha Dhamankar,10,11 Stephanie Dodd,12 Priyanka Kulkarni,13 Andrés Olivares-Morales,14 Chi-Chi Peng,13,15 Xavier Pepin,16 Xiaojun Ren,17 Thuy Tran,18 Christophe Tistaert,19 Tycho Heimbach,20 Filippos Kesisoglou,21 Christian Wagner,22 and Neil Parrott23
Erratum to: The AAPS Journal volume 22, Article number: 123 (2020) https://doi.org/10.1208/s12248-020-00508-2 The BCS classification for furosemide in Table 3 should read IV (not III).
The online version of the original article can be found at https:// doi.org/10.1208/s12248-020-00508-2 1
DMPK and Translational Modeling, AbbVie Inc., North Chicago, Illinois, USA. 2 Global DMPK, Takeda Pharmaceutical Co., Ltd., San Diego, California, USA. 3 Drug Product Technology, Amgen, Thousand Oaks, California, USA. 4 Modeling & Informatics, Vertex Pharmaceuticals, Boston, Massachusetts, USA. 5 Pharmaceutical R&D, Formulation & Process Sciences, F.Hoffmann-La Roche Ltd., Basel, Switzerland. 6 Computational & Modelling Sciences, Platform Technology Sciences, GlaxoSmithKline R&D, Ware, Hertfordshire, UK. 7 Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK. 8 Pharmacokinetic, Pharmacodynamic and Drug MetabolismQuantitative Pharmacology and Pharmacometrics (PPDMQP2),Merck & Co, Inc., West Point, Pennsylvania, USA. 9 Department of Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, California, USA. 10 Formulation Development, Vertex Pharmaceuticals, Boston, Massachusetts, USA. 11 Present Address: Formulation Development, Cyclerion Therapeutics Inc., Cambridge, Massachusetts, USA. 12 Chemical & Pharmaceutical Profiling, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
13
Department of Pharmacokinetics and Drug Metabolism, AmgenInc, Cambridge, Massachusetts, USA. 14 Pharmaceutical Sciences, Roche Pharmaceutical Research andEarly Development, Roche Innovation Center, Basel, Switzerland. 15 Present Address: Drug Metabolism and Pharmacokinetics, Theravance Biopharma, South San Francisco, California, USA. 16 New Modalities and Parenteral Development, PharmaceuticalTechnology & Development, Operations, AstraZeneca, Maccles-field, UK. 17 Modeling & Simulation, PK Sciences, Novartis Institutes of Biomedical Research, East Hanover, New Jersey, USA. 18 Computational & Modelling Sciences, Platform Technology Sciences, GlaxoSmithKline R&D, Collegeville, Pennsylvania, USA. 19 Pharmaceutical Sciences, Janssen Research & Development, Beerse, Belgium. 20 PBPK & Biopharmaceutics, Novartis Institutes of Biomedical Research, Wayne, New Jersey, USA. 21 Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, New Jersey, USA. 22 Pharmaceutical Technologies, Chemical and Pharmaceutical Development, Merck Healthcare KGaA, Darmstadt, Germany
Data Loading...
